



**HAL**  
open science

## Relationship between body mass index and neuropsychiatric symptoms: Evidence and inflammatory correlates

Lison Huet, Ines Delgado, Sandra Dexpert, Julie Sauvante, Bruno Aouizerate, Cédric Beau, Damien Forestier, Patrick Ledaguenel, Eric Magne, Lucile Capuron

### ► To cite this version:

Lison Huet, Ines Delgado, Sandra Dexpert, Julie Sauvante, Bruno Aouizerate, et al.. Relationship between body mass index and neuropsychiatric symptoms: Evidence and inflammatory correlates. *Brain, Behavior, and Immunity*, 2021, 94, pp.104-110. 10.1016/j.bbi.2021.02.031 . hal-03307680

**HAL Id: hal-03307680**

**<https://hal.inrae.fr/hal-03307680>**

Submitted on 24 Apr 2023

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution - NonCommercial 4.0 International License

**Full length article**

**BBI-D-20-00162**

**Manuscript word count: 3,428**

**Figure: 1; Tables: 5**

**Relationship between Body Mass Index and Neuropsychiatric Symptoms:**

**Evidence and Inflammatory Correlates**

Lison Huet<sup>1</sup>, PhD, Ines Delgado<sup>1</sup>, MPh, Sandra Dexpert<sup>1</sup>, MPsy, Julie Sauvant<sup>1</sup>, PhD, Bruno Aouizerate<sup>1,2</sup>, MD-PhD, Cédric Beau<sup>3,4</sup>, MD, Damien Forestier<sup>3,4</sup>, MD, Patrick Ledaguenel<sup>3,4</sup>, MD, Eric Magne<sup>3,4</sup>, MD, Lucile Capuron<sup>1</sup>, PhD

<sup>1</sup> Univ. Bordeaux, INRAE, Bordeaux INP, NutriNeuro, UMR 1286, F-33000, Bordeaux, France

<sup>2</sup> Centre de référence régional des pathologies anxieuses et de la dépression, Hôpital Charles Perrens, F-33076, Bordeaux, France

<sup>3</sup> Service de Chirurgie Digestive et Pariétale, Clinique Tivoli, F-33000, Bordeaux, France

<sup>4</sup> Service de Chirurgie Digestive et Pariétale, Clinique Jean Villar, F-33520, Bruges, France

**Address for correspondence:** Dr Lucile Capuron, INRAE 1286, Laboratory of Nutrition and Integrative Neurobiology (NutriNeuro), University of Bordeaux, 146 rue Léo Saignat, F-33076 Bordeaux, France; Tel. (33) 557571233; Fax. (33) 557571227; Email: [lucile.capuron@inrae.fr](mailto:lucile.capuron@inrae.fr)

## **ABSTRACT**

*Objective:* Neuropsychiatric symptoms are frequent in obese individuals. Mounting evidence suggests that adiposity-related inflammation contributes to this effect. This study assessed the relationship between adiposity, neuropsychiatric symptom dimensions and systemic inflammation in subjects stratified by body-mass-index (BMI).

*Methods:* The study included 165 subjects, of whom 70 were very severely obese (BMI $\geq$ 40 kg/m<sup>2</sup>), 50 severely obese (BMI: 35-39.99 kg/m<sup>2</sup>), 21 overweight or moderately obese (BMI: 25-34.9 kg/m<sup>2</sup>), and 24 lean (BMI<25 kg/m<sup>2</sup>). Depressive symptoms were assessed using the Montgomery-Asberg Depression Rating Scale (MADRS) and the Mini-International Neuropsychiatric Interview (MINI). Fatigue and general neurobehavioral symptoms were assessed using the Multidimensional Fatigue Inventory (MFI) and Neurotoxicity Rating Scale (NRS) respectively. Serum levels of the inflammatory markers, high-sensitive (hs)CRP and hsIL-6, were determined by ELISA.

*Results:* Severely obese subjects exhibited higher MADRS, MFI and NRS scores and were more frequently afflicted with current diagnosis of major depression than lean participants. Scores on psychometric scales were also increased in very severely obese subjects, although to a lesser extent. Alterations in neuropsychiatric dimensions were highly inter-related. HsCRP was significantly increased in subjects with severe or very severe obesity, while hsIL-6 was augmented in all obese groups. Overall, increased neuropsychiatric comorbidity was associated with greater systemic inflammation, notably hsCRP.

*Conclusion:* Obesity is characterized by an increased prevalence of inter-related neuropsychiatric symptoms together with low-grade systemic inflammation augmenting with adiposity. The association between adiposity, systemic inflammation and neuropsychiatric alterations supports the contribution of adiposity-related inflammatory processes to neuropsychiatric comorbidities in obesity. These data suggest that consideration of adiposity characteristics may help identifying subjects at increased risk for neuropsychiatric comorbidity.

Keywords: Obesity; Inflammation; Neuropsychiatric Symptoms; Depression; Prevalence;

Semiology

## INTRODUCTION

Obesity is considered the pandemic of the 21<sup>st</sup> century, representing an important societal and economic burden associated with a greater risk of morbidity and mortality.<sup>1</sup> Its prevalence has dramatically increased during the last decades, with more than 650 million adults being obese worldwide in 2016 according to the last World Health Organization (WHO) estimates. The most commonly used measure of obesity is the Body Mass Index (BMI), calculated as the weight (kg) divided by the square of the height (m). Based on WHO criteria, individuals with a BMI  $\geq$  30 kg/m<sup>2</sup> are considered as being obese, and individuals with a BMI between 25 and 29.9 kg/m<sup>2</sup> are considered as being overweight or preobese. Obesity is further subdivided into severity degrees/classes, corresponding respectively to obesity class I (*moderate obesity*;  $30 \leq \text{BMI} \leq 34.9$  kg/m<sup>2</sup>), obesity class II (*severe obesity*;  $35 \leq \text{BMI} \leq 39.9$  kg/m<sup>2</sup>) and obesity class III (*very severe/massive obesity*; BMI  $\geq 40$  kg/m<sup>2</sup>). Higher degrees of obesity are believed to be associated with an increased risk of comorbidities, including type-2 diabetes and cardiovascular diseases.<sup>2</sup>

Neuropsychiatric complications are also frequent in obese subjects. Accordingly, the prevalence of depression is significantly increased in the obese and obesity represents by itself a potent risk factor for the development of depressive disorders in longitudinal cohort studies.<sup>3-5</sup> The occurrence of depressive symptoms in obese subjects represents a major concern as it strongly impacts quality of life, compromises adherence to treatment and weight management programs and is associated with an increased risk of death by suicide.<sup>6-7</sup> Data from epidemiological surveys indicate that the relationship between obesity and depression is particularly strong in higher degrees of obesity; with subjects afflicted with severe or very severe obesity exhibiting greater rates of depression than subjects with overweight or moderate obesity.<sup>4,8</sup> In line with this, results from a meta-analysis show that being obese significantly increases the risk of depression, notably in women with severe obesity.<sup>9</sup> Fatigue, sleep disturbances and cognitive alterations are also frequently reported in obese subjects.<sup>8</sup> Whether

these alterations are connected in some ways to depressive symptoms or, in contrast, develop in distinct populations of obese subjects remains to be investigated.

The link between obesity and neuropsychiatric comorbidity likely relies on mechanisms that are shared by both conditions.<sup>10,11</sup> Among those mechanisms, adiposity-related inflammation appears critical as mounting evidence supports the role of inflammatory processes in neuropsychiatric symptoms in obese subjects.<sup>12</sup> Obesity is characterized by a chronic low-grade inflammatory state that originates primarily from the adipose tissue in which adipocytes and infiltrated immune cells secrete inflammatory factors.<sup>13,14</sup> Accordingly, the inflammatory state of the visceral adipose tissue was found to correlate with circulating levels of inflammatory markers in subjects with obesity.<sup>14</sup> Alterations in gut permeability and gut microbiota composition are also believed to contribute to the obesity-related inflammatory state, notably by sustaining inflammation in adipocytes.<sup>15,16</sup> Increased blood concentrations of inflammatory markers, including C-reactive protein (CRP) and interleukin-6 (IL-6), have been repeatedly reported in obese subjects.<sup>17-19</sup> Interestingly, those markers significantly correlated with obesity and adiposity indices, such as BMI, waist circumference, and fat distribution.<sup>17,18</sup>

A large database has been developed that substantiates the role of chronic inflammatory processes in the physiopathology of depression and neuropsychiatric symptoms.<sup>20-22</sup> Accordingly, it is likely that adiposity-related chronic inflammation contributes to neuropsychiatric comorbidities in obesity. Consistent with this scenario, we found that systemic inflammation significantly correlates with emotional distress and depressive symptoms in severely obese subjects.<sup>18,19</sup> Interestingly, similar associations were reported with respect to obesity-related cognitive alterations.<sup>23</sup> Supporting further the hypothesis that inflammation represents a key mediator of neuropsychiatric comorbidity in obesity, linear relationships were measured between obesity grades and levels of circulating inflammatory markers,<sup>24</sup> in line with findings reporting greater neuropsychiatric symptoms in severe degrees of obesity.<sup>3-5,8,9</sup> Altogether, these data suggest a preferential association of neuropsychiatric comorbidities with

higher degrees of obesity, probably due to an increased activation of adiposity-related inflammatory processes.

The aim of the present study was to provide a detailed characterization of neuropsychiatric symptom profiles and their relationship with adiposity-related inflammatory status in a sample of subjects stratified by BMI.

## **2. METHODS**

### *2.1 Study participants*

A total of 165 participants were recruited. Since depressive symptoms were shown to be more prevalent in severe and very severe obesity in epidemiological studies<sup>4</sup>, recruitment of individuals from these obesity classes was privileged. Accordingly, fifty participants with severe obesity (BMI: 35-39.99 kg/m<sup>2</sup>) and seventy participants with very severe obesity (BMI  $\geq$  40 kg/m<sup>2</sup>) were included. Additionally, a group of twenty-one participants with overweight or moderate obesity (BMI: 25-34.9 kg/m<sup>2</sup>) and a group of twenty-four healthy lean participants (BMI < 25 kg/m<sup>2</sup>) were included for comparative purposes. Obese subjects were recruited from the services of digestive and parietal surgery of two private clinics (Tivoli and Jean-Villar) in Bordeaux, France. Non-obese participants were either enrolled from the same clinics as obese subjects or through public advertisements.

For all study participants, exclusion criteria were: age > 75 years old; acute or chronic inflammatory conditions (other than obesity or obesity-related comorbidities for the groups of obese subjects); current treatment with antidepressants or any other psychotropic drug; current treatment with anti-inflammatory agents; current diagnosis of psychiatric disease (except for major depression); and/or severe medical illness. The study was approved by the Institutional Ethics Committee for the Protection of Persons (CPP Bordeaux, France). All participants provided written informed consent after reading a complete description of the study.

## *2.2 Clinical and neuropsychiatric assessments*

Socio-demographic (age, gender) and anthropometric variables (BMI, weight) were collected in all participants. Psychiatric antecedents, treatments, obesity history and obesity-related comorbidities, including type-2 diabetes, hypertension (HTA), dysthyroidism, obstructive sleep apnea (OSA) were also gathered.

Depressive symptoms were assessed using the Montgomery-Asberg Depression Rating Scale (MADRS), a clinician administered scale that includes 10 items scored 0 to 6 with higher scores indicating greater symptom severity.<sup>25</sup> Diagnosis of current major depressive disorder (MDD) was determined during a semi-structured interview with a trained clinician using the MINI-International Neuropsychiatric Interview (MINI) according to DSM criteria.<sup>26</sup>

Fatigue symptoms were assessed using the Multidimensional Fatigue Inventory (MFI), a 20-item self-report measuring five dimensions of fatigue including general fatigue, physical fatigue, mental fatigue, reduced activity and reduced motivation. Each dimension contains four items scored 1 to 5 with higher scores reflecting higher severity.<sup>27</sup>

The Neurotoxicity Rating Scale (NRS), a 39-item self-report validated in inflammatory conditions, was used to assess general and neurobehavioral symptoms.<sup>28</sup> Items on the scale are scored 0 “not present” to 4 “extremely severe”. As previously described, NRS symptoms were grouped into four specific symptom dimensions for data analysis, including the dimensions of sickness (tiredness, fever, sick feeling, body aches, joint/muscle pain, headaches), cognitive symptoms (indecisiveness, distractibility, episodes of confusion, word-finding problems, memory impairment), anxiety symptoms (anxiety, tension, irritability, agitation, worries about health) and sleep problems (difficulty getting to sleep or staying asleep, sleeping too much).<sup>29,30</sup> An average score was calculated per dimension to homogenize scores across all dimensions.



### 2.3 Biological measurements

Fasting blood samples were collected the same day as neuropsychiatric assessments for the measurement of serum concentrations of high-sensitive (hs)CRP and hsIL-6. After 30-45 minutes at room temperature, samples were centrifuged (3200 rpm, 10 minutes at 4°C) and sera were stored at -80°C until the assays. Concentrations of inflammatory markers were determined by enzyme-linked immunosorbent assay (ELISA) according to the manufacturer's specifications (hsCRP: CYT298, Millipore, Billerica, Massachusetts; hsIL-6: R&D Systems, Minneapolis, Minnesota). Intra-/inter-assay variability was  $\pm 4.6/6.0\%$  for hsCRP, and  $\pm 7.4/7.8\%$  for hsIL-6. Sensitivities were 0.20 ng/mL for hsCRP and 0.039 pg/mL for hsIL-6.

### 2.4 Data analysis

Clinical and neuropsychiatric variables were assessed using the Chi-square test ( $\chi^2$ ) for categorical variables and analyses of covariance (ANCOVA), controlling for age, gender and comorbidities (type-2 diabetes, dysthyroidism, HTA, OSA) for continuous variables. Post-hoc comparisons were performed using the Tukey test of significance. Of note, data for self-reports (MFI and NRS) were missing in three participants who did not fully complete the questionnaires.

Raw values for hsCRP and hsIL-6 were log-transformed because of non-normality of the distribution, as determined by the Shapiro-Wilk test. Extreme values for hsCRP and/or hsIL-6 ( $> 3$  SD above the mean) were obtained in three participants. Accordingly, data from these subjects were considered as outliers and were excluded from data analyses performed on biological markers. Associations between obesity indices, scores on neuropsychiatric scales and biological variables were assessed using *Bravais-Pearson* correlations. Further, the relationship between neuropsychiatric variables was assessed using a principal component analysis (PCA) in the whole sample under study to assess the interconnection between neuropsychiatric symptoms and to potentially extract reduced and/or specific symptom dimensions. Statistical analyses were performed using XLStat software (StatSoft). Probabilities were two-tailed with the level of

significance set at  $p < 0.05$ .

### 3. RESULTS

#### 3.1 Characteristics of study participants

Characteristics of study participants are shown in **Table 1**. There was no significant differences between groups in terms of age and gender ( $F(3,161) = 1.11$ ,  $p = 0.35$ ;  $\chi^2 = 3.49$ ,  $p = 0.32$ ). As expected, BMI and weight were different across groups ( $F(3,161) = 438.1$ ,  $p < 0.0001$  and  $F(3,161) = 156.4$ ,  $p < 0.0001$ , respectively). Similarly, obesity-related comorbidities, in particular type-2 diabetes ( $\chi^2 = 8.60$ ,  $p = 0.04$ ) and OSA ( $\chi^2 = 24.89$ ,  $p < 0.0001$ ) were more frequent in subjects with very severe obesity and in subjects with severe and very severe obesity, respectively. Interestingly, the proportion of subjects with early onset obesity (obesity since childhood/adolescence) was greater in the group of very severe obesity.

#### 3.2 Neuropsychiatric symptoms

*Depressive symptoms.* As shown in **Figure 1A**, the prevalence of current MDD according to DSM criteria was significantly different across groups ( $\chi^2 = 13.15$ ,  $p < 0.01$ ), with subjects with severe and very severe obesity exhibiting higher prevalence rates than lean controls. Albeit severely obese subjects tended to show increased MDD rates compared to very severely obese participants, this difference did not reach significance level. Consistent with these data, ANCOVA controlling for age, gender and comorbidities revealed significant differences in MADRS total scores between groups ( $F(3,158) = 4.67$ ,  $p < 0.01$ ). In particular, subjects with severe obesity exhibited significantly higher MADRS scores than lean controls ( $p < 0.01$ ) and participants with overweight or moderate obesity ( $p < 0.05$ ) (**Figure 1B**). Analysis performed on individual items of the MADRS scale indicated that this difference was primarily apparent for items of apparent sadness, inability to feel, pessimistic thoughts and suicidal thoughts where, overall, subjects with severe obesity exhibited higher scores (**Table 2**).

*Fatigue symptoms.* MFI total scores were significantly different across groups ( $F(3,155) = 4.92, p < 0.01$ ), with subjects with severe and very severe obesity exhibiting overall higher MFI total scores than lean controls (**Table 3**). Analyses on fatigue symptom dimensions revealed that subjects with severe obesity exhibited greater scores in each dimension of fatigue when compared to lean controls. All obese groups (from overweight to very severe obesity) exhibited higher scores of physical fatigue compared to lean controls.

*Other general and neurobehavioral symptoms.* Overall, NRS total scores were significantly different across groups ( $F(3,154) = 5.87, p < 0.001$ ), with subjects with severe obesity and very severe obesity exhibiting higher scores than lean controls and subjects with overweight or moderate obesity (**Table 3**). This difference was particularly apparent in the NRS dimensions of sickness.

In order to assess the relationship between neuropsychiatric symptom dimensions, a PCA was performed on neuropsychiatric scores (including MADRS total scores, MFI and NRS dimension scores) in the whole population under study. Results indicated that neuropsychiatric scores were highly interconnected as they all loaded in one single factor (eigenvalue = 5.86) explaining 58.6 % of the variance and interpreted as a neuropsychiatric comorbidity factor. Neuropsychiatric comorbidity, indicated by positive scores on this component, was observed in 17.4% of lean participants and in 36.8% of subjects with overweight or moderate obesity. This proportion was increased up to 56% and 44.3% in subjects with severe and very severe obesity respectively.

### *3.3 Obesity-related systemic inflammation and its relationship with neuropsychiatric symptoms*

Circulating concentrations of inflammatory markers across BMI groups are depicted in **Figure 1C-D**. ANCOVA controlling for age, gender and comorbidities indicated a significant difference in hsCRP levels across groups ( $F(3,155) = 59.44 p < 0.0001$ ). In particular, subjects

with severe and very severe obesity were found to exhibit higher levels of hsCRP compared to lean controls and subjects with overweight or moderate obesity (all  $p < 0.001$ ). No difference was found between subjects with severe and very severe obesity and between lean controls and subjects with overweight or moderate obesity with respect to hsCRP levels. Similarly, levels of hsIL-6 were significantly different across groups ( $F(3,155) = 12.45$ ,  $p < 0.0001$ ), with obese subjects, whatever the degree of obesity, exhibiting higher concentrations of this marker than lean controls. In line with this, BMI was highly correlated with hsCRP ( $R=0.633$ ,  $p < 0.0001$ ) and hsIL-6 ( $R=0.428$ ,  $p < 0.0001$ ) in the whole population under study and in the obese groups only ( $R=0.443$ ,  $p < 0.0001$  and  $R=0.216$ ,  $p < 0.05$  respectively). In the whole population under study, levels of hsCRP and hsIL-6 were highly correlated ( $R= 0.493$ ,  $p < 0.0001$ ). The association remained significant when the analysis was restricted to subgroups of obese subjects ( $R= 0.349$ ,  $p < 0.0001$ ).

As shown in **Table 4**, hsCRP and hsIL-6 were individually correlated with neuropsychiatric scores in the whole population under study. Correlations were more frequent with hsCRP that was significantly associated with MADRS total scores, MFI scores of physical fatigue, NRS total scores, and NRS scores of sickness and anxiety. Significant correlations were also measured between hsIL-6 and NRS total scores and scores on the MFI dimensions of physical fatigue and reduced activity. Similarly, scores on the *neuropsychiatric comorbidity factor* were significantly correlated with hsCRP. In line with these data, cross-sectional analyses comparing participants afflicted or not with neuropsychiatric comorbidity (score either negative or positive on the *neuropsychiatric comorbidity factor*) indicated greater levels of hsCRP and hsIL-6 in subjects with neuropsychiatric comorbidity (**Table 5**). These results remained significant when comparisons were adjusted for age, gender and comorbidities.

#### 4. DISCUSSION

To our knowledge, the present study is the first to examine the association between incrementing degrees of adiposity, markers of systemic inflammation and neuropsychiatric symptom profiles in a sample of individuals stratified by BMI. Findings indicate an overall increased neuropsychiatric comorbidity, non-specific to symptom dimensions/profiles, related obesity degrees and systemic inflammation in subjects afflicted with obesity. Accordingly, MDD was found to be more prevalent in subjects with severe or very severe obesity compared to lean controls. Albeit there was no significant difference between severe and very severe obesity with regard to prevalence of MDD, severely obese subjects tended to exhibit higher rates. In line with this, MADRS scores were greater in subjects with severe obesity, notably in items assessing sadness, inability to feel, pessimistic and suicidal thoughts. Fatigue and sickness symptoms, assessed with the MFI and NRS respectively, were also found to be more severe in subjects with severe obesity compared to lean controls. Nevertheless, these symptoms were also apparent in subjects with overweight or moderate obesity (physical fatigue) and in subjects with very severe obesity (physical fatigue and sickness symptoms). Strong associations were found between obesity-related depressive symptoms, fatigue and general neurobehavioral symptoms, providing new insights on the phenomenology of neuropsychiatric symptoms developing in obese subjects. The subtle, but constant, exacerbation of neuropsychiatric symptoms in subjects with severe obesity compared to very severe obesity is also noteworthy. Whereas further investigations are needed to elucidate the reason for this finding, differences in the history/anteriority of obesity in the two groups may be involved. Indeed, and consistent with previous studies<sup>31</sup>, most of subjects with very severe obesity were obese since childhood/adolescence, whereas the proportions early-onset obesity *versus* late-onset obesity were equal in the group of severely obese subjects. Accordingly, it may be that long-term obesity is associated with the development, over time, of psychological compensatory or adjustment strategies that could moderate the impact of obesity on psychological wellbeing.<sup>32</sup> This possibility merits to be assessed in future studies.

In line with previous reports<sup>17-19</sup>, we found strong associations between adiposity and systemic inflammation, reflected in higher hsCRP and hsIL-6 in the groups of obese subjects. While hsCRP levels were primarily increased in subjects with severe and very severe obesity relatively to subjects with overweight or moderate obesity and lean controls, hsIL-6 levels were steadily increased in all obese groups, regardless of obesity severity. Of note, no significant difference was found between subjects with severe and very severe obesity and between lean controls and subjects with overweight or moderate obesity with respect to hsCRP levels. Consistent with previous data and supporting the role of inflammation in obesity-related neuropsychiatric symptoms<sup>18,19,23,33</sup>, hsCRP and hsIL-6 were individually correlated with neuropsychiatric comorbidities in the whole population under study. Associations were stronger for hsCRP that correlated significantly with a large number of neuropsychiatric parameters including depression scores, physical fatigue, sickness and anxiety. HsIL-6 was primarily associated with symptoms of physical fatigue and reduced activity. In line with this, increased neuropsychiatric comorbidity was associated with higher levels of inflammation, in particular hsCRP, in both correlational and cross-sectional analyses. The specific associations found between hsCRP and hsIL6 with neuropsychiatric symptoms were consistent with the differential concentration profiles of these two markers per BMI categories. In particular, the fact that hsCRP was preferentially associated with neuropsychiatric symptoms was coherent with the similarity of distribution of both hsCRP levels and neuropsychiatric symptoms along obesity severity degrees. Similarly, hsIL6 concentrations, which were already increased in low grades of obesity, correlated preferentially with non-specific symptoms (e.g., physical fatigue) that were apparent in all obese subjects, regardless of obesity severity degrees. Altogether, these findings support the involvement of low-grade inflammation in obesity-related neuropsychiatric comorbidity. They suggest that strategies aiming at reducing systemic inflammation could be relevant to improve neuropsychiatric status and reduce the risk of depression in subjects with increased adiposity. Consistent with this notion, weight-loss interventions, including bariatric

surgery, were found to simultaneously reduce systemic inflammation, emotional distress and depressive symptoms in severely obese subjects.<sup>18,34</sup>

The present study includes limitations that future investigations should overcome. Although BMI represents the most common measure of obesity, this index is not fully representative of body fat distribution, notably central adiposity. Compared to the subcutaneous adipose tissue, the visceral adipose tissue is considered as being a more reliable determinant of obesity-related comorbidities. Accordingly, it could be more relevant than BMI with respect to adiposity-related inflammation and its relationship with neuropsychiatric symptoms consistent with data showing associations between central/abdominal adiposity (e.g., waist circumference, waist-to-hip ratio), inflammation and depressive symptoms.<sup>35</sup> Additional measures of fat distribution could help addressing this issue so as to ultimately improve the identification of obese individuals with greater risk of neuropsychiatric comorbidity. It may also be interesting to add assessments of markers involved in the promotion of inflammation, including gut microbiota, endotoxemia, and oxidative stress markers, whose implication in the pathophysiology of neuropsychiatric symptoms has raised significant interest over the last years. Moreover, albeit results were systematically controlled for gender, the high prevalence of women among participants from this study may represent another limitation given the known influence of gender on the association between inflammation and depression.<sup>36,37</sup> In addition, the small and unequal size of study groups may have contributed to reduce the statistical power for detection of significant associations. Finally, the cross-sectional design of the present study does not allow the establishment of a temporal or causal relationship between adiposity-related inflammation and neuropsychiatric symptoms. Large longitudinal studies should be performed to specifically address this issue.

In conclusion, this study provides a detailed picture of the relationship between neuropsychiatric symptoms and inflammatory status, according to obesity severity grades. It shows that obesity is characterized by inter-related neuropsychiatric symptoms, including

depression, fatigue and general behavioral symptoms, together with a chronic low-grade inflammatory state that augment with adiposity degrees. The significant linear association found between adiposity degrees, systemic inflammation and neuropsychiatric alterations strongly supports the involvement of adiposity-related inflammatory processes in neuropsychiatric comorbidities. These data provide new insight on the phenomenology of neuropsychiatric symptoms developing in contexts of obesity. They suggest that the consideration of adiposity characteristics may help to identify subjects with an increased risk of neuropsychiatric comorbidity and to improve the management/treatment of specific subgroups of patients afflicted with neuropsychiatric symptoms.<sup>33</sup> They point to hsCRP as a relevant biomarker of adiposity-related neuropsychiatric symptoms that could help orienting clinical assessment/practice and guiding innovative and personalized treatment strategies targeting inflammatory processes in depressed patients with obesity.

**Acknowledgments.** The authors thank Dr M. Salzmänn-Lovato, Dr J.J. Peroua, Dr C. Duviwier, and medical assistants for their continued help with patients' recruitment.

**Source of funding.** This work was supported by funds from the French National Institute for Agricultural Research (INRA), the French National Research Agency, ANR (ANR-11-JSV1-0006, Dr Capuron), and the *Fondation pour la Recherche Médicale* (DPP20151033943, Dr Capuron).

**Disclosure.** All authors declare no conflicts of interest.



## References

1. Blüher M. Obesity: global epidemiology and pathogenesis. *Nature Reviews Endocrinology*. 2019; 15(5): 288-298.
2. Pantalone KM, Hobbs TM, Chagin KM, et al. Prevalence and recognition of obesity and its associated comorbidities: cross-sectional analysis of electronic health record data from a large US integrated health system. *BMJ Open*. 2017;7(11):e017583.
3. Lasselin J, Capuron L. Chronic low-grade inflammation in metabolic disorders: relevance for behavioral symptoms. *Neuroimmunomodulation*. 2014;21(2-3):95-101.
4. Onyike CU, Crum RM, Lee HB, Lyketsos CG, Eaton WW. Is obesity associated with major depression? Results from the Third National Health and Nutrition Examination Survey. *Am J Epidemiol*. 2003;158(12):1139-1147.
5. Herva A, Laitinen J, Miettunen J, et al. Obesity and depression: results from the longitudinal Northern Finland 1966 Birth Cohort Study. *Int J Obes*. 2006;30(3):520-527.
6. Mazzeschi C, Pazzagli C, Buratta L, et al. Mutual interactions between depression/quality of life and adherence to a multidisciplinary lifestyle intervention in obesity. *J Clin Endocrinol Metab*. 2012; 97: 2261-2265.
7. Mather AA, Cox BJ, Enns MW, Sareen J. Associations of obesity with psychiatric disorders and suicidal behaviors in a nationally representative sample. *J Psychosom Res*. 2009; 66: 277-285).
8. Zhao G, Ford ES, Dhingra S, Li C, Strine TW, Mokdad AH. Depression and anxiety among US adults: associations with body mass index. *Int J Obes*. 2009;33(2):257-266.
9. Jung SJ, Woo HT, Cho S, et al. Association between body size, weight change and depression: systematic review and meta-analysis. *Br J Psychiatry*. 2017;211(1):14-21.

10. Huet L, Delgado I, Aouizerate B, Castanon N, Capuron L. Obesity and depression: shared pathphysiology and translational implications. In: Quevedo J CA, Zarate C, ed. *Neurobiology of Depression*, 1st Edition: Elsevier, Academic Press; 2019:169-183.
11. Milaneschi Y, Simmons WK, van Rossum EFC, Penninx BW. Depression and obesity: evidence of shared biological mechanisms. *Mol Psychiatry*. 2019;24(1):18-33.
12. Capuron L, Lasselin J, Castanon N. Role of Adiposity-Driven Inflammation in Depressive Morbidity. *Neuropsychopharmacology*. 2017;42(1):115-128.
13. Hotamisligil GS. Inflammation, metaflammation and immunometabolic disorders. *Nature*. 2017;542(7640):177-185.
14. Lasselin J, Magne E, Beau C, et al. Adipose inflammation in obesity: relationship with circulating levels of inflammatory markers and association with surgery-induced weight loss. *J Clin Endocrinol Metab*. 2014;99(1):E53-61.
15. Cani PD, Osto M, Geurts L, Everard A. Involvement of gut microbiota in the development of low-grade inflammation and type 2 diabetes associated with obesity. *Gut Microbes*. 2012;3(4):279-288.
16. Hersoug LG, Møller P, Loft S. Gut microbiota-derived lipopolysaccharide uptake and trafficking to adipose tissue: implications for inflammation and obesity. *Obes Rev*. 2016;17(4):297-312.
17. Park HS, Park JY, Yu R. Relationship of obesity and visceral adiposity with serum concentrations of CRP, TNF-alpha and IL-6. *Diabetes Res Clin Pract*. 2005;69(1):29-35.
18. Capuron L, Poitou C, Machaux-Tholliez D, et al. Relationship between adiposity, emotional status and eating behaviour in obese women: role of inflammation. *Psychol Med*. 2011;41(7):1517-1528.
19. Delgado I, Huet L, Dexpert S, et al. Depressive symptoms in obesity: Relative contribution of low-grade inflammation and metabolic health. *Psychoneuroendocrinology*. 2018;91:55-61.

20. Capuron L, Miller AH. Immune system to brain signaling: neuropsychopharmacological implications. *Pharmacol Ther.* 2011;130(2):226-238.
21. Dantzer R, O'Connor JC, Freund GG, Johnson RW, Kelley KW. From inflammation to sickness and depression: when the immune system subjugates the brain. *Nat Rev Neurosci.* 2008;9(1):46-56.
22. Raison CL, Capuron L, Miller AH. Cytokines sing the blues: inflammation and the pathogenesis of depression. *Trends Immunol.* 2006;27(1):24-31.
23. Lasselin J, Magne E, Beau C, et al. Low-grade inflammation is a major contributor of impaired attentional set shifting in obese subjects. *Brain Behav Immun.* 2016;58:63-68.
24. Nguyen XM, Lane J, Smith BR, Nguyen NT. Changes in inflammatory biomarkers across weight classes in a representative US population: a link between obesity and inflammation. *J Gastrointest Surg.* 2009;13(7):1205-1212.
25. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. *Br J Psychiatry.* 1979;134:382-389.
26. Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. *J Clin Psychiatry.* 1998;59 Suppl 20:22-33.
27. Smets EM, Garssen B, Bonke B, De Haes JC. The Multidimensional Fatigue Inventory (MFI) psychometric qualities of an instrument to assess fatigue. *J Psychosom Res.* 1995;39(3):315-325.
28. Valentine AD, Meyers CA, Talpaz M. Treatment of neurotoxic side effects of interferon-alpha with naltrexone. *Cancer Invest.* 1995;13(6):561-566.
29. Capuron L, Gumnick JF, Musselman DL, et al. Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions. *Neuropsychopharmacology.* 2002;26(5):643-652.

30. Capuron L, Schroecksnadel S, Feart C, et al. Chronic low-grade inflammation in elderly persons is associated with altered tryptophan and tyrosine metabolism: role in neuropsychiatric symptoms. *Biol Psychiatry*. 2011;70(2):175-182.
31. Wrzosek M, Wiśniewska K, Sawicka A, Tałałaj M, Nowicka G. Early Onset of Obesity and Adult Onset of Obesity as Factors Affecting Patient Characteristics Prior to Bariatric Surgery. *Obes Surg*. 2018;28(12):3902-3909.
32. Puhl RM, Brownell KD. Confronting and coping with weight stigma: an investigation of overweight and obese adults. *Obesity*. 2006;14(10):1802-15.
33. Shelton RC, Falola M, Li L, Zajecka J, Fava M, Papakostas GI. The pro-inflammatory profile of depressed patients is (partly) related to obesity. *J Psychiatr Res*. 2015;70:91-7.
34. Emery CF, Fondow MD, Schneider CM, et al. Gastric bypass surgery is associated with reduced inflammation and less depression: a preliminary investigation. *Obes Surg*. 2007 Jun;17(6):759-63.
35. Everson-Rose SA, Lewis TT, Karavolos K, Dugan SA, Wesley D, Powell LH. Depressive symptoms and increased visceral fat in middle-aged women. *Psychosom Med*. 2009;71(4):410-416.
36. Kohler-Forsberg O, Buttenschon HN, Tansey KE, et al. Association between C-reactive protein (CRP) with depression symptom severity and specific depressive symptoms in major depression. *Brain Behav Immun*. 2017;62:344-350.
37. Vetter ML, Wadden TA, Vinnard C, et al. Gender differences in the relationship between symptoms of depression and high-sensitivity CRP. *Int J Obes*. 2013;37 Suppl 1:S38-43.

## Figure and Table Legends

### **Figure 1. Depressive symptoms and circulating concentrations of inflammatory markers in obese subjects and lean participants**

*Panels A & B.* Prevalence of current MDD according to DSM criteria (*panel A*) and MADRS total scores (*panel B*) in the study population. Analyses were performed using chi-square test for MDD prevalence and ANCOVA controlling for age, gender and comorbidities for MADRS total scores.

*Panels C & D.* HsCRP (*panel C*) and hsIL-6 (*panel D*) concentrations in the study population. Values were log-transformed for statistical analysis but displayed as raw value geometric means for information and readability purposes. Analyses were performed using ANCOVA controlling for age, gender and comorbidities. Post-hoc comparisons were performed using the Tukey test of significance.

Data are shown as mean (+SEM). \*  $p < 0.05$ ; \*\*  $p < 0.01$ ; \*\*\*  $p < 0.001$ .

*Abbreviations:* CTRL: lean participants; mOB: subjects with overweight or moderate obesity; sOB: subjects with severe obesity; vsOB: subjects with very severe obesity; MADRS: Montgomery-Asberg Depression Rating Scale; MDD: major depressive disorder; hsCRP: high-sensitive C-reactive protein; hsIL-6: high-sensitive interleukin-6; DSM: Diagnostic and Statistical Manual of Mental Disorders; SEM: standard error of the mean.

### **Table 1. Characteristics of study participants**

Analyses were performed using one-way ANOVA for continuous variables and chi-square tests for categorical variables. Post-hoc comparisons were performed using the Tukey test of significance. <sup>a</sup>  $p < 0.001$  vs lean controls; <sup>b</sup>  $p < 0.01$  vs lean controls; <sup>c</sup>  $p < 0.001$  vs overweight or moderate obesity; <sup>d</sup>  $p < 0.01$  vs overweight or moderate obesity; <sup>e</sup>  $p < 0.001$  vs severe obesity.

\*Early onset obesity was considered when obesity was already present at childhood/adolescence

(this information was missing in 2 subjects with overweight or moderate obesity and 4 subjects with severe obesity). *Abbreviations:* BMI: Body Mass Index; HTA: Hypertension; OSA: Obstructive Sleep Apneas; SD: standard deviation.

**Table 2. MADRS item scores across BMI classes**

Analyses were performed using ANCOVA controlling for age, gender and comorbidities. Post-hoc comparisons were performed using the Tukey test of significance. <sup>a</sup>  $p < 0.01$  vs lean controls, <sup>b</sup>  $p < 0.05$  vs lean controls, <sup>c</sup>  $p < 0.05$  vs severe obesity. *Abbreviations:* BMI: Body Mass Index; MADRS: Montgomery-Asberg Depression Rating Scale; SD: standard deviation.

**Table 3. MFI and NRS scores across BMI classes**

Analyses were performed using ANCOVA controlling for age, gender and comorbidities. Post-hoc comparisons were performed using the Tukey test of significance. <sup>a</sup>  $p < 0.01$  vs lean controls, <sup>b</sup>  $p < 0.05$  vs lean controls. \*MFI and NRS scores were missing for 1 lean control and 2 subjects with overweight or moderate obesity. *Abbreviations:* BMI: Body Mass Index; MFI: Multidimensional Fatigue Inventory; NRS: Neurotoxicity rating Scale; SD: standard deviation.

**Table 4. Relationship between systemic inflammation and neuropsychiatric symptoms**

Neuropsychiatric comorbidity factor was extracted from a principal component analysis performed on neuropsychiatric scores. Results are showed as Bravais-Pearson correlations performed on the whole population under study. \*\*\*\*  $p < 0.001$ ; \*\*  $p < 0.01$ ; \*  $p < 0.05$ .

*Abbreviations:* MADRS: Montgomery-Asberg Depression Rating Scale; MFI: Multidimensional Fatigue Inventory; NRS: Neurotoxicity Rating Scale; hsCRP: high-sensitive C-reactive protein; hsIL-6: high-sensitive interleukin-6.

**Table 5. Association between neuropsychiatric comorbidity and adiposity-related systemic inflammation**

Participants were stratified on the basis of their scores on the neuropsychiatric comorbidity factor extracted from the principal component analysis performed on neuropsychiatric scores. Data are shown as mean (+ SEM) compared by Student t-test (*p1*) or ANCOVA controlling for age, gender and comorbidities (*p2*), performed on the whole population under study. *Abbreviations:* hsCRP: high-sensitive C-reactive protein; hsIL-6: high-sensitive interleukin-6; SEM: standard error of the mean.

**Table 1. Characteristics of study participants**

	<b>Lean Controls BMI &lt; 25</b>	<b>Overweight or Moderate Obesity BMI: 25-34.9</b>	<b>Severe Obesity BMI: 35-39.9</b>	<b>Very Severe Obesity BMI ≥ 40</b>	<i>P</i>
Sample size, n					
Age, mean (SD)	44.1 (14.7)	45.7 (17.1)	40.9 (13.1)	41.1 (8.8)	.35
Women, n (%)	21 (88)	16 (76)	38 (76)	61 (87)	.32
BMI, kg/m <sup>2</sup> , mean (SD)	21.6 (2.2)	30.0 (3.5) <sup>a</sup>	37.7 (1.2) <sup>a, c</sup>	44.0 (3.4) <sup>a, c, e</sup>	< .0001
Weight, kg, mean (SD)	58.2 (9.4)	84.2 (14.8) <sup>a</sup>	105.5 (10.4) <sup>a, c</sup>	118.4 (13.7) <sup>a, c, e</sup>	< .0001
Early onset obesity, n (%) <sup>*</sup>	n/a	6 (31.6)	22 (47.8)	46 (65.7) <sup>d</sup>	.01
<b><i>Comorbidities</i></b>					
Type-2 diabetes, n (%)	0 (0)	0 (0)	1 (2)	8 (11) <sup>b, d</sup>	.04
HTA, n (%)	2 (8)	4 (19)	7 (14)	13 (19)	.64
Dysthyroidism, n (%)	3 (13)	2 (10)	4 (8)	6 (9)	.93
OSA, n (%)	0 (0)	3 (17)	18 (41) <sup>b</sup>	35 (53) <sup>b, d</sup>	< .0001



**Table 2. MADRS item scores across BMI classes**

	<b>Lean Controls BMI &lt; 25</b>	<b>Overweight or Moderate Obesity BMI: 25-34.9</b>	<b>Severe Obesity BMI: 35-39.9</b>	<b>Very Severe Obesity BMI ≥ 40</b>	<i>p</i>
<i>MADRS items, mean (SD)</i>					
1. Apparent sadness	0.3 (0.6)	0.5 (0.7)	0.9 (1.2) <sup>b</sup>	0.4 (0.8) <sup>c</sup>	.005
2. Reported sadness	0.6 (0.9)	0.7 (1.0)	1.3 (1.3)	0.9 (1.1)	.04
3. Inner tension	1.1 (1.1)	1.0 (1.0)	1.5 (1.1)	1.2 (1.0)	.24
4. Reduced sleep	0.7 (1.2)	0.9 (1.3)	1.3 (1.4)	1.0 (1.3)	.28
5. Reduced appetite	0.1 (0.3)	0.0 (0.0)	0.2 (0.6)	0.3 (0.8)	.14
6. Concentration difficulties	0.5 (1.0)	0.3 (0.6)	0.8 (1.1)	0.6 (1.1)	.31
7. Lassitude	0.5 (0.8)	0.5 (0.9)	1.1 (1.3)	1.0 (1.3)	.18
8. Inability to feel	0.3 (0.6)	0.5 (1.0)	1.1 (1.3) <sup>b</sup>	0.5 (0.8) <sup>c</sup>	.005
9. Pessimistic thoughts	0.8 (0.9)	1.1 (1.3)	1.7 (1.2) <sup>a</sup>	1.4 (1.3)	.01
10. Suicidal thoughts	0.2 (0.4)	0.3 (0.5)	0.6 (0.8) <sup>a</sup>	0.5 (0.7)	.009

**Table 3. MFI and NRS scores across BMI classes**

	<b>Lean Controls BMI &lt; 25</b>	<b>Overweight or Moderate Obesity BMI: 25-34.9</b>	<b>Severe Obesity BMI: 35-39.9</b>	<b>Very Severe Obesity BMI ≥ 40</b>	<i>p</i>
<i>MFI scores, mean (SD)*</i>					
Total score	38.9 (11.6)	46.3 (12.6)	52.9 (17.2) <sup>a</sup>	48.1 (14.8)	.003
General fatigue	9.8 (3.7)	11.6 (3.7)	12.3 (4.3) <sup>b</sup>	11.2 (3.9)	.05
Physical fatigue	7.9 (3.2)	11.1 (4.0) <sup>b</sup>	12.8 (4.4) <sup>a</sup>	12.3 (4.1) <sup>a</sup>	.0001
Mental fatigue	6.8 (2.3)	7.3 (2.8)	8.9 (3.6) <sup>b</sup>	7.7 (3.5)	.03
Reduced activity	7.5 (3.3)	9.2 (3.4)	10.1 (4.2) <sup>b</sup>	9.1 (3.5)	.05
Reduced motivation	6.9 (2.4)	7.1 (2.6)	8.8 (3.7) <sup>b</sup>	7.9 (3.2)	.03
<i>NRS scores, mean (SD)*</i>					
Total score	17.5 (12.1)	25.0 (15.7)	39.4 (21.9) <sup>a</sup>	35.2 (22.2) <sup>b</sup>	.0008
Cognitive alterations	0.5 (0.5)	0.6 (0.6)	0.8 (0.7)	0.7 (0.7)	.22
Altered sleep	0.8 (0.9)	0.9 (0.6)	1.4 (1.1)	1.0 (0.9)	.07
Sickness symptoms	0.7 (0.5)	1.1 (0.6)	1.6 (0.8) <sup>a</sup>	1.4 (0.8) <sup>a</sup>	< .0001
Anxiety	1.0 (0.8)	0.9 (0.6)	1.4 (0.8)	1.4 (0.7)	.05

**Table 4. Relationship between systemic inflammation and neuropsychiatric symptoms**

	<b>Log hsCRP</b>	<b>Log hsIL-6</b>
<b>Depressive Symptoms</b>		
MADRS total score	.242**	.101
<b>Fatigue</b>		
MFI total score	.124	.151
General fatigue	.048	.055
Physical fatigue	.228**	.232**
Mental fatigue	.132	.107
Reduced activity	.045	.158*
Reduced motivation	.035	.048
<b>General and Neurobehavioral Symptoms</b>		
NRS total score	.264***	.165*
Cognitive alterations	.137	.150
Altered sleep	.151	.101
Sickness symptoms	.290***	.113
Anxiety	.248**	.086
<b>Neuropsychiatric Comorbidity Factor score</b>	.202*	.148

**Table 5. Association of neuropsychiatric comorbidity with adiposity-related systemic inflammation**

	Neuropsychiatric Comorbidity			
	Negative n = 91	Positive n = 69	<i>p1</i>	<i>p2</i>
Log hsCRP	0.41 (0.58)	0.64 (0.52)	0.009	0.025
Log hsIL-6	0.13 (0.31)	0.22 (0.22)	0.041	0.047

FIGURE 1

